Holen Sie sich die Stockscreener-App
660.49
3.29%
21.06
Handel nachbörslich:
662.66
2.17
+0.33%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$639.43
Offen:
$650.4
24-Stunden-Volumen:
6.28M
Relative Volume:
1.46
Marktkapitalisierung:
$625.13B
Einnahmen:
$53.26B
Nettoeinkommen (Verlust:
$13.80B
KGV:
43.17
EPS:
15.3
Netto-Cashflow:
$-50.20M
1W Leistung:
-11.51%
1M Leistung:
-16.71%
6M Leistung:
-24.24%
1J Leistung:
-27.26%
1-Tages-Spanne:
$644.50
$661.75
1-Wochen-Bereich:
$623.78
$678.29
52-Wochen-Spanne:
$623.78
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
660.49 | 573.22B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
174.42 | 416.11B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
201.47 | 350.91B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
121.20 | 230.97B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
82.71 | 200.57B | 63.62B | 16.41B | 14.72B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Texas Sues Eli Lilly: 'Big Pharma Compromised Medical Decision-Making' - Law.com
Jacob van Naarden, Lilly Oncology president, buys $647k in LLY stock - Investing.com
Why Eli Lilly Stock Popped Today - AOL.com
Fund Update: Haverford Trust Co added 38,232 shares of ELI LILLY (LLY) to their portfolio - Quiver Quantitative
Eli Lilly First to Use Germany’s New Confidential Pricing for Mounjaro - Insider Monkey
Jim Cramer on Eli Lilly Stock: “It Just Got Pole-Axed, Laid to Waste” - Insider Monkey
Eli Lilly's $5.9B Houston manufacturing site gets first green light from Texas comptroller - The Business Journals
Why Eli Lilly Stock Popped Today - The Motley Fool
Texas AG sues Eli Lilly over alleged kickbacks as pharma giant eyes $5.9B Houston investment - The Business Journals
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks? - Yahoo Finance
Lilly launches Mounjaro pen in India at $160 for starting dose, stepping up Novo rivalry - Reuters
LLY: Eli Lilly Stock Tanks -- Insiders Rush In With Millions - TradingView
Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound - AOL.com
Eli Lilly stock price target lowered to $825 by Cantor Fitzgerald - Investing.com Nigeria
Eli Lilly (LLY) Expands Mounjaro Availability with New Injector in India - GuruFocus
Texas Accuses Lilly of ‘Bribing’ Prescribers To Push Mounjaro, Zepbound in New Suit - BioSpace
Guggenheim lowers Eli Lilly stock price target on GLP-1 market uncertainty By Investing.com - Investing.com South Africa
Guggenheim lowers Eli Lilly stock price target on GLP-1 market uncertainty - Investing.com
Eli Lilly (LLY) Executives Capitalize on Stock Dip with Signific - GuruFocus
Eli Lilly stock rebounds after insider buying (LLY:NYSE) - Seeking Alpha
Eli Lilly launches Mounjaro KwikPen for diabetes treatment in India - The Economic Times
Novo Nordisk, Eli Lilly and Pfizer apply for inclusion in Chinese health insurance - medwatch.com
Eli Lilly's Mounjaro to land in Korea, setting off price war with Wegovy - Korea JoongAng Daily
Stock Analysis | Eli Lilly OutlookMixed Signals as Earnings Loom and Technicals Turn Cautious - AInvest
Eli Lilly Faces US Lawsuit Over Bribery Allegations - MarketScreener
Top Executives at Eli Lilly & Co Make Major Stock Purchases! - TipRanks
Texas Says Eli Lilly Offered Nursing Services As Kickbacks - Law360
Texas sues, accusing Eli Lilly of 'bribing' physicians to prescribe GLP-1s - Houston Chronicle
These Eli Lilly executives have been scooping up stock after its big drop - MarketWatch
Texas sues Eli Lilly for allegedly bribing providers to push weight loss medications - Dallas News
Texas AG sues Eli Lilly for allegedly bribing medical providers to prescribe Lilly drugs - IndyStar
Texas sues Eli Lilly & Co. for bribing providers to prescribe medications - WISH-TV
Eli Lilly Executives and Directors Engage in Significant Stock Transactions - TradingView
Eli Lilly pledges vigorous defense as Texas sues over alleged drug kickbacks - Fierce Pharma
Texas AG: Eli Lilly and Co. offered kickbacks to providers to prescribe blockbuster drugs - The Indiana Lawyer
Texas Accuses Eli Lilly of Inducing Providers to Prescribe Drugs - Bloomberg Government News
Eli Lilly: The Bears Have Spoken Loud And Clear (Upgrade) (NYSE:LLY) - Seeking Alpha
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications - Reuters
Texas Sues Eli Lilly (LLY) for Allegedly Bribing Doctors to Prescribe Its Drugs - TipRanks
Texas Sues Eli Lilly Over Bribery Allegations: Retail Focuses On Company’s Upbeat Performance By Stocktwits - Investing.com India
Texas Sues Eli Lilly Over Bribery Allegations: Retail Focuses On Company’s Upbeat Performance - Stocktwits
Eli Lilly Sued by Texas for Allegedly Bribing Providers to Prescribe Its Medications - MarketScreener
Eli Lilly's Legal Battles and the Future of Big Pharma's Profitability - AInvest
Eli Lilly sued in Texas suit over illegal kickbacks (LLY) - Seeking Alpha
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications By Reuters - Investing.com
Texas Sues Eli Lilly for Allegedly Bribing Providers to Prescribe Its Medications - U.S. News & World Report
Eli Lilly & Co. (LLY) sued by Texas for allegedly bribing providers to prescribe company's medications - StreetInsider
UK Government, Eli Lilly Partner To Target Obesity Health Gaps - inkl
1 Reason to Buy Eli Lilly (LLY) Stock - The Motley Fool
If You'd Invested $1,000 in Eli Lilly (LLY) Stock 5 Years Ago, Here's How Much You'd Have Today - Mitrade
Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me' - Benzinga
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):